


5 **We claim:**

1. A compound of the general formula (I):



wherein,

10 at each occurrence, R_1 is independently selected from hydrogen, halogen, alkyl or alkoxy;

“A” is alkyl, cycloalkyl or cycloalkylalkyl;

“X” is CH or N;

“Y” is CH_2 , O or $\text{S}=\text{O}$; or its pharmaceutically acceptable salts.

15

2. The compound according to claim 1, which is selected from the group consisting of:

3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one fumarate salt;

20 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one hydrochloride salt;

3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(1,1-dioxo thiomorpholin-4-yl) prop-2-ene-1-one hydrochloride salt;

3-[2-(1-Cyclobutyl piperidin-4-yloxy) pyridin-5-yl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt;

25 3-[2-(1-Cyclobutyl piperidin-4-yloxy) pyridin-5-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;

3-[2-Fluoro-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;

30 3-[2-Fluoro-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;

3-[4-(1-Cyclobutyl piperidin-4-yloxy)-2-methyl phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;

3-[4-(1-Isopropyl piperidin-4-yloxy)-2-methyl phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;

- 5 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one
L(+)-Tartarate salt;
3-[4-(1-Cyclobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one
L(+)-Tartarate salt;
3-[4-(1-Cyclopropylmethyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
10 3-[4-(1-Isobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one
L(+)-Tartarate salt;
3-[4-(1-Isopropyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one
L(+)-Tartarate salt;
15 3-[4-(1-Isopropyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one
L(+)-Tartarate salt;
3-[4-(1-Cyclobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one
L(+)-Tartarate salt;
3-[4-(1-Cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
20 3-[4-(1-Isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
3-[3-Bromo-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
3-[3-Bromo-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
3-[3-Bromo-4-(1-isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
3-[3-Bromo-4-(1-cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
25 3-[6-(1-Cyclopropylmethyl piperidin-4-yloxy) pyridin-3-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
3-[6-(1-Isobutyl piperidin-4-yloxy) pyridin-3-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
30 3-[2-Chloro-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
3-[2-Chloro-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
3-[2-Chloro-4-(1-cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
3-[2-Chloro-4-(1-isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one; or
35 their pharmaceutically acceptable salts.

3. The process for preparation of a compound of formula (I) as claimed in claim 1, which comprises:

- (a) reductive amination of the compound of formula (1) with compound of formula (2)



$$\text{A}=\text{O}$$

(1)

in presence of a suitable solvent and reducing agent to form a compound of formula (I), wherein
10 all substitutions are as defined in claim 1.

(b) optionally converting the compound of formula (I) to their pharmaceutically acceptable salts.

4. A pharmaceutical composition comprising a compound according to any of claims 1 to 2 and pharmaceutically acceptable excipients.

5. The pharmaceutical composition according to claim 4, for the treatment of clinical conditions mediated through H₃ receptor such as cognitive deficits in schizophrenia, narcolepsy, obesity, attention deficit hyperactivity disorder, pain or alzheimer's disease.

20

6. Use of a compound according to any one of the claims 1 to 2 in the manufacture of medicament for the treatment of diseases related to Histamine H_1 receptors.

25 7. The use of compound according to the claim 6, for the treatment of clinical conditions such as cognitive deficits in schizophrenia, narcolepsy, obesity, attention deficit hyperactivity disorder, pain or alzheimer's disease.

30

35